Literature DB >> 10867156

A novel high throughput screening assay for HCV NS3 helicase activity.

M Hicham Alaoui-Ismaili1, C Gervais, S Brunette, G Gouin, M Hamel, R F Rando, J Bedard.   

Abstract

A novel assay for measurement of Hepatitis C virus (HCV) NS3 helicase activity was developed using Flashplate technology. This assay involves the use of a DNA duplex substrate and recombinant HCV NS3 produced in Escherichia coli. The DNA duplex consisted of a pair of oligonucleotides, one biotinylated, the other radiolabeled at their respective 5' termini. This DNA duplex was immobilized, via the biotin molecule, on the surface of a neutravidin-coated SMP103 Flashplate (NEN Life Science Products). Helicase activity results in the release of the radiolabeled oligonucleotide, which translates in signal reduction with respect to control wells. Biochemical characterization of the HCV NS3 helicase activity was performed using this assay. We demonstrated that the NS3-mediated unwinding is proportional to both the amount of DNA substrate in the well, and to the NS3 concentration in the reaction. Most of the NS3-mediated unwinding was achieved in the initial 60 min of incubation. As expected the reactions were ATP-dependent and found to be affected by the concentration of MgCl(2), MnCl(2), KCl, EDTA, and by pH. We found this assay to be highly reproducible since only slight variation was observed when a total of 68 helicase reactions were performed on one plate. Therefore, this Flashplate helicase assay is fast, convenient and reproducible. These criteria make it suitable for high throughput screening of potential NS3 helicase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10867156     DOI: 10.1016/s0166-3542(00)00085-1

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  14 in total

1.  Helicase inhibitors as specifically targeted antiviral therapy for hepatitis C.

Authors:  Craig A Belon; David N Frick
Journal:  Future Virol       Date:  2009-05-01       Impact factor: 1.831

Review 2.  Helicases as antiviral drug targets.

Authors:  David N Frick
Journal:  Drug News Perspect       Date:  2003 Jul-Aug

3.  Monitoring helicase activity with molecular beacons.

Authors:  Craig A Belon; David N Frick
Journal:  Biotechniques       Date:  2008-10       Impact factor: 1.993

4.  Investigating a new generation of ribozymes in order to target HCV.

Authors:  Michel V Lévesque; Dominique Lévesque; Francis P Brière; Jean-Pierre Perreault
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

5.  Exploitation of lipid components by viral and host proteins for hepatitis C virus infection.

Authors:  Kohji Moriishi; Yashiharu Matsuura
Journal:  Front Microbiol       Date:  2012-02-14       Impact factor: 5.640

6.  Target-dependent on/off switch increases ribozyme fidelity.

Authors:  Lucien Junior Bergeron; Jean-Pierre Perreault
Journal:  Nucleic Acids Res       Date:  2005-02-24       Impact factor: 16.971

7.  Induction of cell-mediated immune responses in mice by DNA vaccines that express hepatitis C virus NS3 mutants lacking serine protease and NTPase/RNA helicase activities.

Authors:  Suratno Lulut Ratnoglik; Da-Peng Jiang; Chie Aoki; Pratiwi Sudarmono; Ikuo Shoji; Lin Deng; Hak Hotta
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

8.  A modern mode of activation for nucleic acid enzymes.

Authors:  Dominique Lévesque; Francis P Brière; Jean-Pierre Perreault
Journal:  PLoS One       Date:  2007-07-25       Impact factor: 3.240

Review 9.  Discovering new medicines targeting helicases: challenges and recent progress.

Authors:  William R Shadrick; Jean Ndjomou; Rajesh Kolli; Sourav Mukherjee; Alicia M Hanson; David N Frick
Journal:  J Biomol Screen       Date:  2013-03-27

Review 10.  A new helicase assay based on graphene oxide for anti-viral drug development.

Authors:  Hongje Jang; Soo-Ryoon Ryoo; Min Jae Lee; Sang Woo Han; Dal-Hee Min
Journal:  Mol Cells       Date:  2013-03-11       Impact factor: 5.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.